MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s12916-025-04477-1

Медицинская библиотека · BMC medicine · 2025

Dabigatran-based versus warfarin-based triple antithrombotic regimen with a 1-month intensification after coronary stenting in patients with nonvalvular atrial fibrillation (COACH-AF PCI).

Liang Ming, Jin Jun, Zhao Ruiping, Li Hui, Chen Shaoliang, Liu Limin, Xu Ping, Wang Wei, Cheng Xiang, Chen Xuezhi, Tao Ling, Zhang Qi, Yang Ming, Zeng Chunyu, Li Li, Zheng Yi, Chen Hong, Guo Jincheng, Zhong Zhixiong, Bi Yayan, Cheng Biao, Zhou Yujie, Wang Hong, Zhang Yujie, Qiu Miaohan, Zhang Qi, Zhang Ping, Zhang Jie, Wang ZuLu, Li Yi, Han Yaling

Клиническое исследование IV фазыСравнительное исследованиеСтатьяМногоцентровое исследованиеРандомизированное исследованиеПеревод в очереди

Аннотация

BACKGROUND

To assess the safety and efficacy of dabigatran-based triple antithrombotic (TAT) regimen in patients after percutaneous coronary intervention (PCI) with atrial fibrillation (AF).

METHODS

A multicenter, open-label, randomized controlled trial across 50 Chinese hospitals enrolled nonvalvular AF patients after coronary stenting. Participants were randomly assigned to receive dabigatran (110 mg twice/daily) or warfarin-based TAT regimen (dabigatran or warfarin with aspirin and clopidogrel) for 1 month and then convert to dual antithrombotic therapy (dabigatran or warfarin with clopidogrel) for 6 months. The primary safety endpoint was the first occurrence of clinically relevant bleeding (BARC types 2-5). Secondary endpoints included net adverse clinical events (NACEs) and major or clinically relevant non-major bleeding (CRNB). And the efficacy endpoint was the major adverse cardiac and cerebral events (MACCEs).

RESULTS

The study was terminated early due to COVID-19 impacting recruitment. A total of 540 patients were enrolled. BARC types 2-5 bleeding occurred in 8.0% and 4.3% of patients in warfarin and dabigatran groups, respectively (HR 0.54; 95% CI 0.26-1.09; P = 0.0861). And total bleeding events (BARC 1-5) were 20.5% and 9.4% (HR 0.44; 95% CI 0.27-0.70; P = 0.0005). Dabigatran showed a lower total bleeding risk than warfarin, with similar risks for BARC types 2-5 bleeding, NACEs, CRNB, major bleeding, and MACCEs.

CONCLUSIONS

Among AF patients underwent PCI, the dabigatran-based TAT regimen did not significantly reduce the rate of BARC types 2-5 bleeding at 6 months compared with warfarin-based regimen, although the power of the study to find a difference was low due to early termination (COACH-PCI, NCT03536611, https://clinicaltrials.gov/show/NCT03536611 ).

Для цитирования: Liang Ming, Jin Jun, Zhao Ruiping, Li Hui, Chen Shaoliang, Liu Limin, Xu Ping, Wang Wei, Cheng Xiang, Chen Xuezhi, Tao Ling, Zhang Qi, Yang Ming, Zeng Chunyu, Li Li, Zheng Yi, Chen Hong, Guo Jincheng, Zhong Zhixiong, Bi Yayan, Cheng Biao, Zhou Yujie, Wang Hong, Zhang Yujie, Qiu Miaohan, Zhang Qi, Zhang Ping, Zhang Jie, Wang ZuLu, Li Yi, Han Yaling. Dabigatran-based versus warfarin-based triple antithrombotic regimen with a 1-month intensification after coronary stenting in patients with nonvalvular atrial fibrillation (COACH-AF PCI).. BMC medicine. 2025. DOI: 10.1186/s12916-025-04477-1.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.